Non-hodgkin Lymphoma,B CellPhase 1/2NCT05631912
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL
A Phase 1/2 study testing Autologous CD19-STAR-T cell, Fludarabine and Cyclophosphamide in people with Non-hodgkin Lymphoma,B Cell, run by Chinese PLA General Hospital at 2 sites in China.
Trial summary
The team has developed a chimeric antigen receptor (CAR) based on T cell receptor (TCR) complex, called synthetic TCR and antigen receptor (STAR). Further, the researchers disrupted the endogenous T-cell receptor α constant (TRAC) locus by CRISPR/cas9, and then knocked in the anti-CD19-STAR construct through TRAC… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Non-hodgkin Lymphoma,B Cell
- What is being tested?
- Autologous CD19-STAR-T cell, Fludarabine and Cyclophosphamide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 2 sitesChina
- Study dates
- 30 Jun 2023to 15 Dec 2025
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-75 (inclusive).
- Patients with histologically confirmed CD19-positive B-cell NHL, including the following types defined by the World Health Organization (WHO) 2016:
- Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), including Activated B-cell type (ABC) / Germinal center B-cell Type (GCB);
- Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);
- Transformed follicular lymphoma (TFL);
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBCL);
Show all 34Show fewer
- Follicular lymphoma (FL);
- Mantle cell lymphoma (MCL) [pathologically confirmed, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1];
- Marginal zone lymphoma (MZL), including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma.
- Relapse after treatment with ≥2 lines systemic therapy for all the above disease types, or refractory disease for aggressive types (DLBCL-NOS, PMBCL, TFL and HGBCL). Relapse disease is defined as disease progression after last regimen. Refractory disease is defined as no CR to first-line therapy:
- PD as best response to first-line therapy, or
- SD as best response after at least 4 cycles of first-line therapy (eg, 4 cycles of R-CHOP), or
- PR as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤ 6 months of therapy, or
- Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or relapsed less than or equal to 12 months of ASCT (must have biopsy proven recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy.
- Individuals must have received adequate prior therapy:
- For MCL, prior therapy must have included:
- Anthracycline or bendamustine-containing chemotherapy and
- Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
- Bruton's tyrosine kinase inhibitor (BTKi)
- For other types, prior therapy must have included:
- Anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20-negative) and
- Anthracycline containing chemotherapy regimen.
- For individual with transformed FL must have relapse or refractory disease after transformation to DLBCL.
- The estimated survival time is over 3 months.
- The Eastern Cooperative Oncology Group (ECOG) score is 0-2.
- According to Lugano response criteria 2014, there should be at least one evaluable tumor focus. Evaluable tumor focus was defined as that with the longest diameter of intranodal focus > 1.5cm, the longest diameter of extranodal focus > 1.0cm assessed by computed tomography (CT) or magnetic resonance imaging (MRI).
- Subjects must be willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides.
- Functions of important organs meet the following requirements: Echocardiography showed left ventricular ejection fraction ≥50%. Serum creatinine ≤1.5 × upper limit of normal range (ULN) or endogenous creatinine clearance ≥45mL/min (cockcroft-gault formula); Alanine ULN, Total bilirubin ≤1.5× ULN; Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) ≥91% in indoor air environment.
- Blood routine (normal values shall not be obtained with growth factors, and hemocytopenia caused by lymphoma invasion of bone marrow is not subject to conditions below): hemoglobin (Hgb) ≥80g/L, neutrophil count (ANC) ≥1×10^6/L, platelet (PLT) ≥75×10^9/L.
- Pregnancy tests for women of childbearing age shall be negative; Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.
- Toxicity from previous antitumor therapy ≤ grade 1 (according to CTCAE version 5.0) or to an acceptable level of inclusion/exclusion criteria (other toxicities such as alopecia and vitiligo considered by the investigator to pose no safety risk to the subject).
- No obvious hereditary diseases.
- Able to understand the requirements and matters of the trial, and willing to participate in clinical research as required.
- Informed consent must be signed.
Who cannot join
- During the screening period, there was central nervous system (CNS) invasion or a history of clinically significant central nervous system diseases, such as epilepsy and cerebrovascular diseases.
- Women who are pregnant or breastfeeding, or who do not agree to use effective contraception during treatment and during the subsequent 1 year.
- History of allogeneic hematopoietic stem cell transplantation, or organ transplantation.
- History of other malignancies that have not been in remission.
- Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy.
- Received radiotherapy within 3 months before enrollment.
Show all 19Show fewer
- Received immunotherapy drugs within 4 weeks before enrollment, such as anti-programmed death 1 (PD-1) antibody, anti-programmed death ligand 1 (PD-L1) antibody, CD19/CD3-bispecific antibody, and so on.
- Patients who received any immunocellular therapy within 6 months before enrollment.
- Confirmed evidence showing positiveness of anti-CD19 scFv reaction in patient serum.
- Patients who participated in other clinical trials within 4 weeks prior to enrollment.
- Uncontrolled infectious diseases or other serious illnesses, including but not limited to infections [e.g., human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B (HBV) or C (HCV) infection], congestive heart failure, unstable angina, arrhythmias, or that pose an unpredictable risk in the opinion of the attending physician.
- The presence of uncontrollable serous membrane fluid, such as massive pleural effusion or ascites.
- A history of stroke or intracranial hemorrhage within 3 months prior to enrollment.
- Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.
- History of allergies to any of the ingredients in cell products.
- Conditions in which a known mental or physical illness interferes with cooperation with the requirements of the study or disrupts the results or interpretation of the results and, in the opinion of the therapeutic investigator, makes the patient unfit for study participation.
- There is the situation that the researcher's judgment will interfere with the whole study participation; Situations where there is significant risk to the subject; Or interferes with the interpretation of research data.
- Inability to understand or unwillingness to sign informed consent.
- Researchers believe that other reasons are not suitable for clinical trials.
Trial locations and contacts
2 sites in 1 country.
China2 sites, 2 recruiting
- Recruiting
Biotherapeutic Department, Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853
Weidong Han, Ph.D, +86-010-66937463, hanwdrsw@sina.com
Yang Liu, M.D., +86-010-66937463, liuyang301blood@163.com
- Recruiting
School of medicine, Tsinghua University & Changping Laboratory
Beijing, Beijing Municipality
Xin Lin, Ph.D, +86-010-62796319, linxin307@mail.tsinghua.edu.cn
Xin Lin, Ph.D
About this study
Official title: Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The team has developed a chimeric antigen receptor (CAR) based on T cell receptor (TCR) complex, called synthetic TCR and antigen receptor (STAR). Further, the researchers disrupted the endogenous T-cell receptor α constant (TRAC) locus by CRISPR/cas9, and then knocked in the anti-CD19-STAR construct through TRAC endogenous promoter. In this single center, prospective, open-label, single-arm, phase 1/2 study, the safety and efficacy of autologous CD19-targeting STAR-T cell therapy will be evaluated in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (B-NHL) . A total of 19 to 38 patients are planned to be enrolled and receive CD19-STAR-T cell infusion. Phase 1 (9 to 18 cases) is dose escalation part, and phase 2 (10 to 20 cases) is expansion cohort part.
Read the detailed description
[Introduction]
At present, CAR-T cell therapy targeting CD19 has achieved remarkable efficacy in the treatment of r/r B-NHL. However, at the same time, CAR-T cell treatment has a high incidence of cytokine release syndrome (CRS), immune cell-associated neurotoxicity syndrome (ICANS) and other toxicities. TCR-T is another adoptive T cell therapy, which recognizes the surface and intracellular antigens of target cells presented by major histocompatibility complex (MHC) molecules and engage CD3 signaling machinery, triggering a wide range of TCR-CD3 signaling to kill tumors. TCR-T is characterized by high affinity with target antigen, low toxicity, but difficulty in preparation.
Here, the researchers connected the murine TCR constant regions α and β with the light chain and heavy chain of the murine FMC63 single-chain variable fragment (scFv) respectively to construct a human leukocyte antigen (HLA)-independent antibody TCR chimera, called synthetic T cell receptor and antigen receptor (STAR). Then, researchers introduced an additional interchain disulfide bond by making cysteine mutations within TCRα/β constant regions, and employed hydrophobic substitutions to the TCR-α chain transmembrane domain to improve the receptor's stability on plasma membrane.
Further, the team disrupted the endogenous TRAC locus by CRISPR/cas9, and then knocked in the CD19-STAR construct to this locus, and transcription of CD19-STAR triggered by the TRAC endogenous promoter. TRAC locus knockout can prevent endogenous TCR assembly, and avoid the harm caused by graft-versus host disease (GVHD) as well as random insertion. This specific integration of "two in one" technology can give rise to highly efficient expression of CD19-STAR chimeric molecule on T cell surface, and the subsequent assembly of complete TCR signaling structure.
The molecular structure of STAR in this study: the variable region of TCRα/β chain is replaced with the heavy chain and light chain of FMC63 antibody respectively, the intracellular region of α/β chain is connected with an OX40 costimulatory molecule respectively.
STAR integrates the advantages of TCR and CAR, and is close to the natural TCR-antigen action mode with high affinity, high sensitivity, and low T cell exhaustion. Compared with TCR-T, it is easier to obtain and prepare. The researchers confirmed that the CD19-STAR-T cells, by in vitro and in vivo assays, had lower cytokine release but more efficient anti-tumor activities when compared to canonical CAR-T cells. In this study, we would like to evaluate the safety and efficacy of autologous TRAC locus-inserted CD19-STAR-T cell in r/r patients with r/r B-NHL . The completion of this trial will provide a research foundation for potential universal allogeneic adoptive T cell therapy.
[Study design]
Phase 1 (dose escalation)
In phase 1, 9 to 18 subjects will be enrolled. Subjects will receive 3 doses of CD19-STAR-T cell therapy (1 × 10^6 cells/kg, 3 × 10^6 cells/kg, 1 × 10^7 cells/kg) from low dose to high dose according to the "3 + 3" principle:
- Three patients were enrolled in the lowest dose group.
- Subsequent patients were enrolled according to the following rules:
- If the incidence of dose limiting toxicity (DLT) was 0/3, 3 patients were enrolled in the next high-dose group.
- If the incidence of DLT was 1/3, 3 patients were enrolled at the same dose; If the incidence of DLT was 1/3 + 0/3, 3 patients were enrolled in the next high-dose group. If the incidence of DLT was 1/3 + 1/3, this dose was defined as maximum tolerated dose (MTD); If the incidence of DLT was 1/3 + 2/3 or 1/3 + 3/3, the previous dose was MTD.
- If the incidence of DLT was 2/3 or 3/3, the previous dose was MTD.
To ensure the safety of the subjects, the first subject in each dose group was observed for at least 28 days after the cell infusion. If no DLT occurred, the remaining two subjects could be enrolled and treated at the same dose level. The safety data of all subjects in each dose group until day 28 should be reviewed and tolerated before proceeding to the next dose group trial. No dose escalation was allowed for the same subject during the trial. If a subject drop out during the observation period due to non-DLT reasons, new subjects should be enrolled to make up for the number of subjects who drop out.
Phase 2 (expansion cohort)
In phase 2, 10 to 20 subjects will be enrolled and receive CD19-STAR-T cell infusion at dose of RP2D, which will be determined based on the MTD, occurrence of DLT, the obtained efficacy results, pharmacokinetics / pharmacodynamics and other data according to the phase 1.
[Objectives]
The primary objectives of the phase 1 were to evaluate the tolerability, safety, and determine recommended phase 2 dose (RP2D). The primary purpose of the phase 2 study was to evaluate the efficacy.
- Conditions
- Non-hodgkin Lymphoma,B Cell
- Being tested
- Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous CD19-STAR-T cellBiological
Also called Autologous CD19-targeting synthetic T-cell receptor antigen receptor T cells
Phase 1 dose escalation (3+3) : dose 1 (1×10^6 cells/kg) ,dose 2 (3×10^6 cells/kg) ,dose 3 (1×10^7 cells/kg); Phase 2 : Appropriate dose
FludarabineDrug
Also called Fludarabine Phosphate for Injection
Intravenous fludarabine 25-30 mg/m^2/day on days -5, -4, and -3.
CyclophosphamideDrug
Also called Cyclophosphamide for Injection
Intravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3.
| Study group | Role | What they receive |
|---|---|---|
| Autologous TRAC locus-inserted CD19-targeting STAR-T cells | Experimental | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous targeting CD19 synthetic T-cell receptor antigen receptor T cells.
Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control. Receives: Biological: Autologous CD19-STAR-T cell; Drug: Fludarabine; Drug: Cyclophosphamide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 1: Incidence of Adverse Events (AEs)
AE is defined as any adverse medical event from the date of randomization to 12 months after CD19-STAR-T cells infusion. Among them, CRS and ICANS were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.
Measured: 12 months
Phase 1: Incidence of Dose-Limiting Toxicities (DLTs)
DLT was defined as CD19-STAR-T cells-related events with onset within first 28 days following infusion: The development of Grade (G) 3 or higher grade CRS lasting > 2 weeks; Any CD19-STAR-T cells-related AE requiring intubation; All G4 non-hematologic toxicities.
Measured: First infusion date of CD19-STAR-T cells up to 28 days
Phase 1: Maximum tolerated dose (MTD)
MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.
Measured: 12 months
Phase 1: Recommended phase 2 dose (RP2D)
The recommended dose for phase 2 was determined through phase 1 study.
Measured: 12 months
Phase 2: Best objective Response Rate
The incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as the best response to treatment assessed by investigators and based on the Lugano 2014 assessment criterion.
Measured: 12 months
Secondary outcomes (7)
Phase 2: Overall Survival (OS)
OS is defined as the time from CD19-STAR-T cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.
Measured: 12 months after the first infusion of CD19-STAR-T cells
Phase 2: Progression Free Survival (PFS)
PFS is defined as the time from the CD19-STAR-T cells infusion date to the date of disease progression assessed by investigators and based on the Lugano 2014 assessment criterion, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Measured: 12 months after the first infusion of CD19-STAR-T cells
Phase 2: Time to response (TTR)
TTR is defined as the time from CD19-STAR-T infusion to first assessed CR or PR by investigators and based on the Lugano 2014 assessment criterion.
Measured: 12 months
Phase 2: Duration of Response (DOR)
DOR is defined as the date of their first CR or PR (which is subsequently confirmed) to PD assessed by investigators and based on the Lugano 2014 assessment criterion for r/r B-cell NHL, or death regardless of cause.
Measured: 12 months
Pharmacokinetics: Number and copy number of CD19-STAR-T cells (phase 1 and phase 2)
Number and copy number of CD19-STAR-T cells were assessed by number in peripheral blood. Blood samples were collected before and one year after cell infusion (until CD19-STAR-T cells were not detected for two consecutive times) to detect the number and copy number of CD19-STAR-T cells, and to evaluate the pharmacokinetics of CD19-STAR-T.
Measured: 12 months
Pharmacokinetics: Persistence of CD19-STAR-T (phase 1 and phase 2)
Persistence of CD19-STAR-T cell assessed by number in peripheral blood.
Measured: 12 months
Pharmacodynamics: Peak level of cytokines in serum (phase 1 and phase 2)
The cytokines mainly include interleukin-2 (IL-2 ), IL-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), C reactive protein (CRP), ferritin. Peak was defined as the maximum post-baseline level of the cytokine.
Measured: Up to 28 days after infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2022
- Study start30 Jun 2023
- Primary completion15 Dec 2024 (estimated)
- Study completion15 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-hodgkin Lymphoma,B CellStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Han weidong, Chinese PLA General Hospital
- Investigators
- Weidong Han, Ph.D, Principal investigator, Biotherapeutic Department, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05631912
- Sponsor's protocol ID
- CHN-PLAGH-BT-073
- Status last verified
- Jul 2023
- First submitted
- 21 Nov 2022
- Last updated
- 6 Jul 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- ClinicalTrials.gov ID
- NCT05631912
- Acronym / sponsor ID
- CHN-PLAGH-BT-073
- Conditions
- Non-hodgkin Lymphoma,B Cell
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Study start
- 30 Jun 2023 (actual)
- Primary completion
- 15 Dec 2024 (estimated)
- Study completion
- 15 Dec 2025 (estimated)
- First posted
- 30 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The team has developed a chimeric antigen receptor (CAR) based on T cell receptor (TCR) complex, called synthetic TCR and antigen receptor (STAR). Further, the researchers disrupted the endogenous T-cell receptor α constant (TRAC) locus by CRISPR/cas9, and then knocked in the anti-CD19-STAR construct through TRAC endogenous promoter. In this single center, prospective, open-label, single-arm, phase 1/2 study, the safety and efficacy of autologous CD19-targeting STAR-T cell therapy will be evaluated in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (B-NHL) . A total of 19 to 38 patients are planned to be enrolled and receive CD19-STAR-T cell infusion. Phase 1 (9 to 18 cases) is dose escalation part, and phase 2 (10 to 20 cases) is expansion cohort part.
Detailed description
[Introduction]
At present, CAR-T cell therapy targeting CD19 has achieved remarkable efficacy in the treatment of r/r B-NHL. However, at the same time, CAR-T cell treatment has a high incidence of cytokine release syndrome (CRS), immune cell-associated neurotoxicity syndrome (ICANS) and other toxicities. TCR-T is another adoptive T cell therapy, which recognizes the surface and intracellular antigens of target cells presented by major histocompatibility complex (MHC) molecules and engage CD3 signaling machinery, triggering a wide range of TCR-CD3 signaling to kill tumors. TCR-T is characterized by high affinity with target antigen, low toxicity, but difficulty in preparation.
Here, the researchers connected the murine TCR constant regions α and β with the light chain and heavy chain of the murine FMC63 single-chain variable fragment (scFv) respectively to construct a human leukocyte antigen (HLA)-independent antibody TCR chimera, called synthetic T cell receptor and antigen receptor (STAR). Then, researchers introduced an additional interchain disulfide bond by making cysteine mutations within TCRα/β constant regions, and employed hydrophobic substitutions to the TCR-α chain transmembrane domain to improve the receptor's stability on plasma membrane.
Further, the team disrupted the endogenous TRAC locus by CRISPR/cas9, and then knocked in the CD19-STAR construct to this locus, and transcription of CD19-STAR triggered by the TRAC endogenous promoter. TRAC locus knockout can prevent endogenous TCR assembly, and avoid the harm caused by graft-versus host disease (GVHD) as well as random insertion. This specific integration of "two in one" technology can give rise to highly efficient expression of CD19-STAR chimeric molecule on T cell surface, and the subsequent assembly of complete TCR signaling structure.
The molecular structure of STAR in this study: the variable region of TCRα/β chain is replaced with the heavy chain and light chain of FMC63 antibody respectively, the intracellular region of α/β chain is connected with an OX40 costimulatory molecule respectively.
STAR integrates the advantages of TCR and CAR, and is close to the natural TCR-antigen action mode with high affinity, high sensitivity, and low T cell exhaustion. Compared with TCR-T, it is easier to obtain and prepare. The researchers confirmed that the CD19-STAR-T cells, by in vitro and in vivo assays, had lower cytokine release but more efficient anti-tumor activities when compared to canonical CAR-T cells. In this study, we would like to evaluate the safety and efficacy of autologous TRAC locus-inserted CD19-STAR-T cell in r/r patients with r/r B-NHL . The completion of this trial will provide a research foundation for potential universal allogeneic adoptive T cell therapy.
[Study design]
Phase 1 (dose escalation)
In phase 1, 9 to 18 subjects will be enrolled. Subjects will receive 3 doses of CD19-STAR-T cell therapy (1 × 10^6 cells/kg, 3 × 10^6 cells/kg, 1 × 10^7 cells/kg) from low dose to high dose according to the "3 + 3" principle:
- Three patients were enrolled in the lowest dose group.
- Subsequent patients were enrolled according to the following rules:
- If the incidence of dose limiting toxicity (DLT) was 0/3, 3 patients were enrolled in the next high-dose group.
- If the incidence of DLT was 1/3, 3 patients were enrolled at the same dose; If the incidence of DLT was 1/3 + 0/3, 3 patients were enrolled in the next high-dose group. If the incidence of DLT was 1/3 + 1/3, this dose was defined as maximum tolerated dose (MTD); If the incidence of DLT was 1/3 + 2/3 or 1/3 + 3/3, the previous dose was MTD.
- If the incidence of DLT was 2/3 or 3/3, the previous dose was MTD.
To ensure the safety of the subjects, the first subject in each dose group was observed for at least 28 days after the cell infusion. If no DLT occurred, the remaining two subjects could be enrolled and treated at the same dose level. The safety data of all subjects in each dose group until day 28 should be reviewed and tolerated before proceeding to the next dose group trial. No dose escalation was allowed for the same subject during the trial. If a subject drop out during the observation period due to non-DLT reasons, new subjects should be enrolled to make up for the number of subjects who drop out.
Phase 2 (expansion cohort)
In phase 2, 10 to 20 subjects will be enrolled and receive CD19-STAR-T cell infusion at dose of RP2D, which will be determined based on the MTD, occurrence of DLT, the obtained efficacy results, pharmacokinetics / pharmacodynamics and other data according to the phase 1.
[Objectives]
The primary objectives of the phase 1 were to evaluate the tolerability, safety, and determine recommended phase 2 dose (RP2D). The primary purpose of the phase 2 study was to evaluate the efficacy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Autologous TRAC locus-inserted CD19-targeting STAR-T cells | Experimental | Biological: Autologous CD19-STAR-T cell, Drug: Fludarabine, Drug: CyclophosphamideA conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous targeting CD19 synthetic T-cell receptor antigen receptor T cells. Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (34 listed)
- Age 18-75 (inclusive).
- Patients with histologically confirmed CD19-positive B-cell NHL, including the following types defined by the World Health Organization (WHO) 2016:
- Relapse after treatment with ≥2 lines systemic therapy for all the above disease types, or refractory disease for aggressive types (DLBCL-NOS, PMBCL, TFL and HGBCL). Relapse disease is defined as disease progression after last regimen. Refractory disease is defined as no CR to first-line therapy:
- Individuals must have received adequate prior therapy:
- The estimated survival time is over 3 months.
Key exclusion criteria (19 listed)
- During the screening period, there was central nervous system (CNS) invasion or a history of clinically significant central nervous system diseases, such as epilepsy and cerebrovascular diseases.
- Women who are pregnant or breastfeeding, or who do not agree to use effective contraception during treatment and during the subsequent 1 year.
- History of allogeneic hematopoietic stem cell transplantation, or organ transplantation.
- History of other malignancies that have not been in remission.
- Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous CD19-STAR-T cellAlso: Autologous CD19-targeting synthetic T-cell receptor antigen receptor T cellsPhase 1 dose escalation (3+3) : dose 1 (1×10^6 cells/kg) ,dose 2 (3×10^6 cells/kg) ,dose 3 (1×10^7 cells/kg); Phase 2 : Appropriate dose | Biological | Autologous TRAC locus-inserted CD19-targeting STAR-T cells |
| FludarabineAlso: Fludarabine Phosphate for InjectionIntravenous fludarabine 25-30 mg/m^2/day on days -5, -4, and -3. | Drug | Autologous TRAC locus-inserted CD19-targeting STAR-T cells |
| CyclophosphamideAlso: Cyclophosphamide for InjectionIntravenous cyclophosphamide 300-500 mg/m^2/day on days -5, -4, and -3. | Drug | Autologous TRAC locus-inserted CD19-targeting STAR-T cells |
Primary outcome
Phase 1: Incidence of Adverse Events (AEs)
Time frame: 12 months
AE is defined as any adverse medical event from the date of randomization to 12 months after CD19-STAR-T cells infusion. Among them, CRS and ICANS were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.
Phase 1: Incidence of Dose-Limiting Toxicities (DLTs)
Time frame: First infusion date of CD19-STAR-T cells up to 28 days
DLT was defined as CD19-STAR-T cells-related events with onset within first 28 days following infusion: The development of Grade (G) 3 or higher grade CRS lasting > 2 weeks; Any CD19-STAR-T cells-related AE requiring intubation; All G4 non-hematologic toxicities.
Phase 1: Maximum tolerated dose (MTD)
Time frame: 12 months
MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.
Phase 1: Recommended phase 2 dose (RP2D)
Time frame: 12 months
The recommended dose for phase 2 was determined through phase 1 study.
Phase 2: Best objective Response Rate
Time frame: 12 months
The incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as the best response to treatment assessed by investigators and based on the Lugano 2014 assessment criterion.
7 secondary outcomes
Phase 2: Overall Survival (OS)
Time frame: 12 months after the first infusion of CD19-STAR-T cells
Phase 2: Progression Free Survival (PFS)
Time frame: 12 months after the first infusion of CD19-STAR-T cells
Phase 2: Time to response (TTR)
Time frame: 12 months
Phase 2: Duration of Response (DOR)
Time frame: 12 months
Pharmacokinetics: Number and copy number of CD19-STAR-T cells (phase 1 and phase 2)
Time frame: 12 months
Pharmacokinetics: Persistence of CD19-STAR-T (phase 1 and phase 2)
Time frame: 12 months
Pharmacodynamics: Peak level of cytokines in serum (phase 1 and phase 2)
Time frame: Up to 28 days after infusion
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2023.
- Individual participant dataSharing planned: No
Related trials for Non-hodgkin Lymphoma,B Cell
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
RecruitingPhase 3
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
B-Cell Acute Lymphoblastic Leukaemia
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Weidong Han, Ph.D principal investigator
Biotherapeutic Department, Chinese PLA General Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Autologous CD19-STAR-T cell, Fludarabine and Cyclophosphamide in people with Non-hodgkin Lymphoma,B Cell, run by Chinese PLA General Hospital at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 34 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Weidong Han, Ph.D (+86-010-55499341, hanwdrsw@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase 1: Incidence of Adverse Events (AEs) (time frame: 12 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2023.